Specialty Medicine Compounding Pharmacy is voluntarily recalling all lots of certain unexpired human and veterinary sterile products to the consumer level due to particulate matter found in vials of a compounded dextrose injection product dispensed to a local hospital. Further testing and analysis of the medication is being conducted.

Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary nationwide recall to the user level for one lot of 0.25% Marcaine™ (Bupivacaine HCl Injection, USP), 75 mg/30 mL, Single-dose Vial – Preservative Free (NDC 0409-1559-30), Lot 25-220-DD. The recall is due to a confirmed customer report of discolored solution with visible particles inside the glass vial as well as embedded in the glass.

FAHMAN ENTERPRISES INC. of Dallas, TX is voluntarily recalling PRAN TURMERIC POWDER because it was found to contain high levels of lead that could cause health problems to consumers, particularly infants, small children, and pregnant women if consumed. The recall was initiated after it was discovered that product contained high levels of lead (48 ppm) based on sampling by The Food and Drug Administration.

Nephron Pharmaceuticals Corporation (NPC) has initiated a voluntary recall, at the retail level, as a precautionary measure, due to results from our internal monitoring processes. NPC is asking retailers to remove the affected lots from store shelves and is asking consumers to discontinue use and dispose of any product they may have that is included in this recall.

GE Healthcare has initiated a voluntary field corrective action for the Engström ventilator and Aespire View, Aisys, and Avance anesthesia machines due to a potential safety issue. The affected units were manufactured between the dates of April 23, 2013 and July 22, 2013.

BEST VALUE, INC. of Detroit, MI is voluntarily recalling PRAN TURMERIC POWDER because it was found to contain high levels of lead that could cause health problems to consumers, particularly infants, small children, and pregnant women if consumed. The recall was initiated after it was discovered that product contained high levels of lead (53 ppm) based on sampling by Food and Drug Administration.

GE Healthcare has initiated a voluntary field corrective action for the Avance, Aisys and Avance CS2 anesthesia delivery systems with 8.00 (Avance and Aisys) or 10.00 (Avance CS2) software due to a potential safety issue. The affected units were manufactured from February 2011 through July 2013.

B. Braun Medical Inc. (B.Braun) is voluntarily recalling one lot of 1g Cefepime for Injection USP and Dextrose Injection USP (Lot H3A744, catalog 3193-11) to the consumer level. The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit.